Resource Central is a product of the Pediatric Pandemic Network.

Nirsevimab Library

This is a collection of current resources related to Nirsevimab.

Cost-Effectiveness of Nirsevimab and Palivizumab for Respiratory Syncytial Virus Prophylaxis in Preterm Infants 29-34 6/7 Weeks' Gestation in the United States
2024 · University of Southern California
This study compares the cost-effectiveness of two drugs, nirsevimab and palivizumab, used to prevent respiratory syncytial virus (RSV) in preterm infants born between 29 and …

Looking for different way to find resources?

Our chatbot aRCie can help with a more personalized search. Click below to try our new chatbot.

Try aRCie